GlassScriptPhysician profile
Jalal Baig
NPI 1740647437
$3,602.89
in general payments reported to CMS, 2019-2025
26 companies · $98.19 in 2025
The $98.19 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.73 · 2021: $247 · 2022: $228 · 2023: $2,202 · 2024: $810 · 2025: $98.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,665 · Food and Beverage: $1,355 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,665.00 |
| Food and Beverage | $1,355.03 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,766.37 | 2023-2025 | Imfinzi, Tagrisso |
| Novartis Pharmaceuticals Corporation | $543.32 | 2019-2025 | |
| Gilead Sciences, INC. | $265.85 | 2023-2024 | Trodelvy |
| Amgen INC. | $201.97 | 2021-2023 | Lumakras, Nplate, Xgeva |
| Seagen INC. | $84.92 | 2021-2023 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $82.48 | 2021-2023 | Imbruvica |
| Emd Serono, INC. | $65.91 | 2022-2023 | Tepmetko, Bavencio |
| Pfizer INC. | $65.32 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $60.24 | 2024 | Libtayo |
| Morphosys, US INC. | $48.33 | 2022-2023 | Monjuvi |
| Astellas Pharma US INC | $44.23 | 2024 | Padcev, Xtandi |
| Jazz Pharmaceuticals INC. | $38.07 | 2023 | Zepzelca |
| Cti Biopharma Corp. | $35.79 | 2023 | Vonjo |
| Global Blood Therapeutics, INC. | $33.00 | 2022 | |
| Daiichi Sankyo INC. | $27.18 | 2025 | Enhertu |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $27.17 | 2022 | |
| Springworks Therapeutics, INC. | $24.65 | 2024 | Ogsiveo |
| Array Biopharma INC | $22.44 | 2024 | Braftovi, Lorbrena, Xalkori |
| Puma Biotechnology, INC. | $22.37 | 2023 | |
| Eisai INC. | $22.26 | 2024 | |
| Deciphera Pharmaceuticals INC. | $22.19 | 2023 | Qinlock |
| Abbvie INC. | $22.04 | 2024 | |
| Servier Pharmaceuticals LLC | $20.55 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.35 | 2024 | Ultomiris |
| Tersera Therapeutics LLC | $20.13 | 2024 | Zoladex |
| Adaptive Biotechnologies Corporation | $15.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jalal Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.